

HR 1843

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Congress: 119 (2025–2027, Current)

Chamber: House

Policy Area: Health

Introduced: Mar 5, 2025

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Mar 5, 2025)

Official Text: <https://www.congress.gov/bill/119th-congress/house-bill/1843>

Sponsor

Name: Rep. Dunn, Neal P. [R-FL-2]

Party: Republican • **State:** FL • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Mullin, Kevin [D-CA-15]	D · CA		Mar 5, 2025

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Mar 5, 2025

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
119 HR 7148	Related bill	Feb 3, 2026: Became Public Law No: 119-75.
119 S 1302	Related bill	Apr 3, 2025: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
119 S 891	Related bill	Mar 6, 2025: Read twice and referred to the Committee on Finance.
119 HR 1768	Related bill	Mar 3, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, the Budget, the Judiciary, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary (as of Mar 5, 2025)

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

- Mar 5, 2025:** Referred to the House Committee on Energy and Commerce.
- **Mar 5, 2025:** Introduced in House
 - **Mar 5, 2025:** Introduced in House
 - **Mar 5, 2025:** Referred to the House Committee on Energy and Commerce.
 - **Mar 5, 2025:** Introduced in House
 - **Mar 5, 2025:** Introduced in House
 - **Mar 5, 2025:** Referred to the House Committee on Energy and Commerce.
 - **Mar 5, 2025:** Introduced in House
 - **Mar 5, 2025:** Introduced in House
 - **Mar 5, 2025:** Referred to the House Committee on Energy and Commerce.
 - **Mar 5, 2025:** Introduced in House
 - **Mar 5, 2025:** Referred to the House Committee on Energy and Commerce.